Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moxifloxacin Kabi, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections, including community‑acquired pneumonia, complicated intra‑abdominal infections, skin and soft tissue infections, and acute bacterial sinusitis in adult patients.

GNH USA supplies Moxifloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moxifloxacin Kabi, a fluoroquinolone antibacterial, is indicated for several serious bacterial infections.

Community‑acquired bacterial pneumonia: rapid bacterial eradication and clinical improvement. Complicated intra‑abdominal infections: effective coverage of mixed aerobic and anaerobic pathogens. Skin and soft tissue infections: resolution of infection in cellulitis, abscesses and wound infections. Acute bacterial sinusitis: relief of sinus inflammation and bacterial clearance.

Moxifloxacin Kabi may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: often self‑limiting watery stools. - Headache: transient cranial discomfort. - Dizziness: occasional vertiginous sensations. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of ventricular arrhythmias. - Clostridioides difficile‑associated diarrhea: severe colitis. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic failure: rare but potentially fatal liver injury. - Seizures: especially in patients with CNS disorders.

Use of Moxifloxacin Kabi requires careful clinical assessment and monitoring.

Renal impairment: adjust dosing and monitor renal function. Hepatic dysfunction: use with caution; monitor liver enzymes. History of tendon disorders: avoid use due to risk of tendon rupture. Concomitant QT‑prolonging drugs: monitor ECG and electrolytes. Pregnancy and lactation: safety not established; weigh benefits against risks. Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin Kabi can interact with several drug classes, affecting safety or efficacy.

Major Interactions (Avoid): - Other fluoroquinolones: additive toxicity. - Antacids containing aluminum or magnesium: markedly reduced absorption. - Warfarin: enhanced anticoagulant effect, increased INR.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of CNS stimulation. - Corticosteroids: heightened risk of tendon rupture. - CYP450 inhibitors (e.g., ciprofloxacin): potential alteration of plasma concentrations.